Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Gilead Sciences exercised its possibility license a Kymera Therapeutics’ protein-degrading drug designed to get rid of the cancer-driving protein CDK2. ...
Tag: Degraders
ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of Interest & More
Bispecific antibodies are one of the most active areas of cancer research, and pharmaceutical companies are busy striking deals to ...
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!